Antimineralocorticoid activity of a novel oral contraceptive containing XXXX , a unique progestogen resembling natural @entity1420 .

@entity172 @entity1369 @entity6112 @entity1420 @entity2178 @entity2082 @entity4 @entity1372 @entity4863 @entity1017 @entity916
Sex hormones are known to interfere with the @entity916 -angiotensin- @entity1369 system (RAAS) in two ways. First, @entity172 strongly stimulate the production of @entity916 substrate ( @entity2178 ), leading to increased levels of angiotensin and @entity1369 , and @entity1372 retention. Second, @entity1420 is a potent @entity1369 antagonist, which acts on the mineralocorticoid receptor to prevent @entity1372 retention. In combined oral contraceptives, progestogens devoid of antimineralocorticoid and antiandrogenic activity are unable to counteract the @entity1372 -retaining effect of the @entity2082 component. As a consequence, these preparations may increase @entity6112 , and promote related symptoms such as @entity4 and body weight. @entity4863 is a new progestogen with antimineralocorticoid and antiandrogenic activity. The relationship between the progestogenie and antimincralocorticoid potency of @entity4863 is similar to that of endogenous @entity1420 . At a dosage that suppresses ovulation, @entity4863 induces mild natriuresis, which is followed by compensatory stimulation of the RAAS (comparable to a low @entity1372 diet). An oral contraceptive containing 3 mg @entity4863 and 30 microg @entity2082 . (Yasmin, Schering AG, Berlin, Germany) provides reliable contraception and, due to a lack of @entity1372 retention, may counteract cyclical @entity1017 and other symptoms related to @entity172 -induced @entity6112 .
